Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?
Vera Himmelsbach,Christine Koch,Jörg Trojan,Fabian Finkelmeier
DOI: https://doi.org/10.2147/jhc.s443218
2024-02-19
Journal of Hepatocellular Carcinoma
Abstract:Vera Himmelsbach, Christine Koch, Jörg Trojan, Fabian Finkelmeier Department of Gastroenterology, Hepatology and Endocrinology, University Hospital Frankfurt, Frankfurt, Germany Correspondence: Jörg Trojan, Medizinische Klinik 1, Klinikum der Johann Wolfgang Goethe-Universität, Theodor-Stern-Kai 7, Frankfurt, 60590, Germany, Tel +49 069 6301 7860, Fax +49 69 6301 6448, Email Liver cancer was the fourth leading cause of cancer death in 2015 with increasing incidence between 1990 and 2015. Orthotopic liver transplantation, surgical resection and ablation comprise the only curative therapy options. However, due to the late manifestation of clinical symptoms, many patients present with intermediate or advanced disease, resulting in no curative treatment option being available. Whereas intermediate-stage hepatocellular carcinoma (HCC) is usually still addressable by transarterial chemoembolization (TACE), advanced-stage HCC is amenable only to pharmacological treatments. Conventional cytotoxic agents failed demonstrating relevant effect on survival also because their use was severely limited by the mostly underlying insufficient liver function. For a decade, tyrosine kinase inhibitor (TKI) sorafenib was the only systemic therapy that proved to have a clinically relevant effect in the treatment of advanced HCC. In recent years, the number of substances for systemic treatment of advanced HCC has increased enormously. In addition to tyrosine kinase inhibitors, immune checkpoint inhibitors (ICI) and antiangiogenic drugs are increasingly being applied. The combination of anti-programmed death ligand 1 (PD-L1) antibody atezolizumab and anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has become the new standard of care for advanced HCC due to its remarkable response rates. This requires more and more complex clinical decisions regarding tumor therapy. This review aims at summarizing recent developments in systemic therapy, considering data on first- and second-line treatment, use in the neoadjuvant and adjuvant setting and combination with locoregional procedures. Keywords: hepatocellular carcinoma, systemic therapy, checkpoint inhibitors, neoadjuvant treatment, adjuvant treatment Hepatocellular carcinoma (HCC) is the most common primary liver cancer and develops in 80–90% due to liver cirrhosis. 1 Therefore, in addition to tumor stage, the presence and extent of the liver cirrhosis, as well as the underlying disease of the cirrhosis, are major factors in evaluating the various therapeutic options. As the prognosis is significantly influenced by liver function and any underlying disease, the BCLC classification (Barcelona Clinic Liver Classification) for HCC 2 also includes liver function and ECOG status (Eastern Cooperative Oncology Group) in addition to tumor extent. In early stages (BCLC 0 and A), resection, as well as local ablative procedures are also available as curative therapy options. HCC recurrence after resection or ablation occurs in 70–80%. 3 In order to evaluate their effectiveness on recurrence free survival (RFS), neoadjuvant and adjuvant therapies were performed in the context of clinical trials. 3–5 In the intermediate stage (BCLC B), when no curative therapy options are available, transarterial chemoembolization (TACE) or radioembolization (TARE) can be performed if liver function is preserved. 6,7 Resection, transcutaneous ablation, and transarterial procedures can also be applied for bridging and downstaging to liver transplantation. 8,9 For HCC patients with distant metastases or intrahepatic tumor manifestation that is not resectable and cannot be controlled by locoregional procedures, the antiproliferative and antiangiogenic tyrosine kinase inhibitor (TKI) sorafenib has been approved since November 2007. 10 Since its approval, the multityrosine kinase inhibitor sorafenib was the only option in systemic treatment of HCC available for a decade. In the past five years, there have been fundamental changes in terms of systemic therapy options for advanced HCC. With the TKI lenvatinib showing non-inferiority to sorafenib a second option for systemic therapy was established in 2018. 11 In 2020, the combination of the immune checkpoint inhibitor (ICI) atezolizumab (anti-PD-L1 antibody) and the antiangiogenic bevacizumab (anti-VEGF antibody) proved superiority in the IMBRAVE-150 trial to sorafenib and is since then considered the standard of care in systemic first-line treatment of HCC. 12,13 Limiting factors in the application of atezolizumab and bevacizumab are liver function and the individual patient's risk of variceal bleeding. 12–14 There have also been advances in second-line therapy in recent years: The TKI regorafenib is very similar to sorafenib in terms of molecular -Abstract Truncated-
oncology